menu
    • menu
    [{"orgOrder":0,"company":"ConSynance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ConSynance Therapeutics Reports Positive Phase 1 Results for CSTI-500 in Prader-Willi Syndrome Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"CSTI-500","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ConSynance Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ConSynance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ConSynance.."},{"orgOrder":0,"company":"ConSynance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ConSynance Receives Rare Pediatric Disease Designation for CSTI-500 in PW Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CSTI-500","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ConSynance Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ConSynance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"ConSynance.."}]

    Find Clinical Drug Pipeline Developments & Deals by ConSynance Therapeutics

    Menu

    ConSynance Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ConSynance Therapeutics

                            U.S.A arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            ConSynance Therapeutics

                            U.S.A arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CSTI-500

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ConSynance Receives Rare Pediatric Disease Designation for CSTI-500 in PW Syndrome

                            Details : CSTI-500 is a first-in-class, oral, triple monoamine reuptake inhibitor, small molecule drug candidate being evaluated for the treatment of prader-willi syndrome in children and adolescents.

                            Product Name : CSTI-500

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 24, 2024

                            Lead Product(s) : CSTI-500

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ConSynance Therapeutics

                            U.S.A arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            ConSynance Therapeutics

                            U.S.A arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CSTI-500

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ConSynance Therapeutics Reports Positive Phase 1 Results for CSTI-500 in Prader-Willi Syndrome Pat...

                            Details : CSTI-500 is a first-in-class, orally administered new chemical entity and an optimally balanced Triple Monoamine Reuptake inhibitor (TRI). It is being investigated for the treatment for prader-willi syndr...

                            Product Name : CSTI-500

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 30, 2023

                            Lead Product(s) : CSTI-500

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth